Esperion Therapeutics Prices Public Offering of Common Stock
Esperion Therapeutics Prices Public Offering of Common Stock
October 15, 2014
J.P. Morgan and BofA Merrill Lynch are acting as joint book-running
managers for the offering with
The securities described above are being offered by Esperion pursuant to
a shelf registration statement on Form S-3 (No. 333-197125) including a
base prospectus. The securities may be offered only by means of a
prospectus. A preliminary prospectus supplement related to the offering
was filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding the therapeutic potential of, and
clinical development plan for, ETC-1002 and statements pertaining to our
expectations regarding the completion and anticipated proceeds of the
proposed public offering. These statements are based on management's
current expectations and accordingly are subject to uncertainty and
changes in circumstances. Actual results could differ materially from
those anticipated due to certain risks and uncertainties including,
without limitation, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the public
offering. There can be no assurance that Esperion will be able to
complete the public offering on the anticipated terms, or at all. Any
express or implied statements contained in this press release that are
not statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements involve risks and uncertainties
that could cause Esperion's actual results to differ significantly from
those projected, including, without limitation, the risk that positive
results from a clinical study of ETC-1002 may not necessarily be
predictive of the results of future clinical studies, particularly in
different or larger patient populations, or the risk that other
unanticipated developments could interfere with the development (and
commercialization) of ETC-1002, as well as other risks detailed in
Esperion's filings with the
Media Contact:
212.257.6724
efox@w2ogroup.com
or
Investor
Contact:
734.887.3903
mlowe@esperion.com
Source:
News Provided by Acquire Media